Maxcyte (MXCT) Other Operating Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Other Operating Expenses data on file, last reported at $3.4 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $3.4 million, up 131.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.0 million (up 34.81% YoY), and the FY2025 annual result was -$46.5 million, up 2.61% from the prior year.
• Other Operating Expenses improved to $3.4 million in Q1 2026 per MXCT's latest filing, from -$9.6 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $8.3 million in Q4 2023 and troughed at -$13.2 million in Q3 2024.
• A 5-year average of -$2.2 million and a median of $3.4 million in 2026 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2026: Other Operating Expenses plunged 263.61% in 2024, then soared 131.26% in 2026.
• A 5-year view of Other Operating Expenses shows it stood at $6.3 million in 2022, then soared by 32.15% to $8.3 million in 2023, then sank by 248.56% to -$12.3 million in 2024, then climbed by 21.8% to -$9.6 million in 2025, then surged by 135.58% to $3.4 million in 2026.
• Business Quant data shows MXCT's Other Operating Expenses at $3.4 million in Q1 2026, -$9.6 million in Q4 2025, and -$12.4 million in Q3 2025.